Rabies Vaccine Vero Cell Against Rabies Virus Infection

As a specialized vaccine manufacturer and supplier based in China, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. delivers critical biological products to protect populations worldwide from the fatal rabies virus. Produced under strict GMP standards in our state-of-the-art facility, our inactivated rabies vaccine represents our unwavering commitment to global public health. As part of AIM Vaccine Group—the second-largest rabies vaccine manufacturer globally—we leverage advanced Vero cell culture technology and a domestically developed aG virus strain to ensure high potency and reliable immunogenicity for all populations.

Product Overview

Rabies remains one of the most feared infectious diseases worldwide, with a near-100% fatality rate once clinical symptoms appear. Effective vaccination is the cornerstone of rabies prevention and control programs globally. Understanding the fundamental properties of the vaccine is essential for healthcare providers and procurement professionals alike.

The Rabies Vaccine Vero Cell Against Rabies Virus Infection is a freeze-dried preparation of rabies fixed virus (aGV strain) grown in Vero cells. After cultivation and harvest, the virus suspension undergoes inactivation, concentration, and purification processes, followed by lyophilization with stabilizers. The final product appears as a white crisp cake that transforms into a clear liquid after reconstitution.

Composition:

1. Active ingredient: Inactivated rabies fixed virus (aGV strain)

2. Excipients: 1% human albumin, 1% gelatin, 5% sucrose, PBS

3. Diluent: Sterile water for injection

This vaccine contains no preservatives, offering an enhanced safety profile suitable for sensitive populations. It works by stimulating the recipient's immune system to produce specific neutralizing antibodies against the rabies virus, providing active immunity that helps prevent the onset of disease following exposure.

Indications & Use

This section describes the appropriate use and administration guidelines for the Rabies Vaccine Vero Cell Against Rabies Virus Infection, which is indicated for the prevention of rabies in humans across all age groups. It can be used for both pre-exposure prophylaxis for individuals at high risk of occupational exposure and post-exposure prophylaxis for those who have been bitten or scratched by suspect animals.

Eligible Individuals:

1. Post-exposure: Any person bitten or scratched by a rabid animal, regardless of age or sex. Wounds should be cleaned immediately with soap and water, followed by iodine tincture or ethanol application before vaccination.

2. Pre-exposure: Individuals at risk of contacting rabies virus, such as veterinarians, animal breeders, forestry workers, slaughterhouse workers, and rabies laboratory staff.

Wound Category Classification:

1. Category I: Petting an animal or licked on intact skin without breaks — no wound treatment or vaccination necessary.

2. Category II: Bitten or scratched without bleeding — vaccination following post-exposure schedule is required.

3. Category III: Single or multiple biting wounds with bleeding, scratches with bleeding, or mucous membrane contamination by animal saliva — immediate vaccination combined with rabies immunoglobulin is required.

Immunization Schedules:

1. Post-exposure: Five doses administered on days 0, 3, 7, 14, and 28. For certain conditions including immunodeficiency, elderly patients, or delayed vaccination beyond 48 hours, doubling the first dose is recommended.

2. Pre-exposure: Three doses given on days 0, 7, and 21 or 28 for individuals with ongoing exposure risk.

3. Re-immunization: Varies based on previous immunization history, ranging from two booster doses (days 0 and 3) for recently immunized patients to a complete re-immunization schedule for those vaccinated more than three years ago.

The vaccine is administered via intramuscular injection in the deltoid muscle of the upper arm. For young children, the anterolateral aspect of the thigh is the recommended injection site. Proper administration technique and strict adherence to the immunization schedule are critical for ensuring optimal protection and seroconversion.

Specifications

Accurate product specifications are vital for procurement planning, inventory management, and clinical use. The Rabies Vaccine Vero Cell Against Rabies Virus Infection is manufactured to precise standards with clearly defined parameters that ensure consistency and reliability across every batch.

These specifications are maintained through rigorous quality control measures at every stage of production. Each batch undergoes comprehensive testing before release, ensuring that all parameters meet or exceed the required standards set by national pharmacopoeia and international guidelines.

Manufacturing Quality

The quality of a vaccine is directly determined by its manufacturing process. The Rabies Vaccine Vero Cell Against Rabies Virus Infection is produced in our GMP-certified facility that adheres to the highest international standards, combining advanced technology with strict quality control to deliver products that healthcare providers can trust.

Key Production Processes:

1. Advanced purification technology: Utilizes a 20m² ultrafiltration system and 600mm chromatography system for multi-step purification, effectively removing foreign proteins, DNA, and other impurities to ensure high antigen purity that meets global standards.

2. Strict quality control: Implements internal control standards stricter than national pharmacopoeia requirements, including endotoxin ≤10 EU/dose, sterile growth in sterility tests, and precise pH value control to ensure product quality stability and consistency.

3. Standardized freeze-drying technology: Uses a 40m² freeze-drying system that reduces moisture content to extend shelf life while maintaining antigen activity. The entire formulation process is controlled in a B+A grade clean environment, ensuring product safety.

4. Closed sterile culture system: Bacterial culture and passage processes are completed in a fully enclosed sterile operation system under B+A grade clean conditions throughout. The operation team wears fully enclosed protective equipment and strictly follows sterile standards for strain passage and cell expansion to avoid external contamination.

Equipped with high-precision culture equipment, the facility precisely controls parameters such as temperature and pH to ensure strain activity and cell proliferation stability. This process is one of the core links ensuring the purity and activity of vaccine antigens, laying a high-quality foundation for subsequent purification and formulation processes.

Safety Profile

Vaccine safety is paramount in public health programs. The Rabies Vaccine Vero Cell Against Rabies Virus Infection has been extensively used and has a well-established safety profile. Understanding potential adverse reactions and contraindications helps healthcare providers administer the vaccine safely and effectively.

Common Adverse Reactions:

1. Local reactions: Redness, swelling, pain, or itching at the injection site within 24 hours — these typically resolve spontaneously without treatment.

2. Systemic reactions: Low fever, malaise, headache, dizziness, arthralgia, myalgia, vomiting, or abdominal pain — these are usually mild and resolve without specific treatment.

Rare Adverse Reactions:

1. Moderate to severe fever: Transient fever may require physical therapy or symptomatic treatment to prevent febrile convulsions.

Extremely Rare Adverse Reactions:

1. Allergic rash: Urticaria may occur generally within 72 hours after vaccination; anti-anaphylactic treatment should be administered promptly.

2. Anaphylactic shock: May occur within one hour after vaccination; emergency treatment including prompt injection of adrenaline is required immediately.

3. Allergic purpura: Requires prompt medical attention and anti-anaphylactic treatment with corticosteroids; delayed treatment may lead to purpuric nephritis.

4. Angioneurotic edema or nervous system reactions: Require timely medical treatment and close monitoring.

Contraindications:

1. Post-exposure immunization: No absolute contraindications exist, as rabies is a fatal disease and the benefits of vaccination far outweigh any risks.

2. Pre-exposure immunization: Should not be administered to individuals with known allergic reactions to any vaccine component including excipients and antibiotics; patients with acute diseases, severe chronic diseases at acute attack stage, or fever; individuals with uncontrolled epilepsy or other progressive nervous system diseases.

Storage: Store and ship the product between +2°C and +8°C, protected from light. Proper cold chain management is essential for maintaining vaccine potency and safety throughout its 36-month validity period.

Why Choose AIM

Selecting the right vaccine supplier is a critical decision that impacts supply reliability, product quality, and ultimately, public health outcomes. AIM Honor stands as a trusted partner for global procurement, backed by the strength and expertise of AIM Vaccine Group.

Our Competitive Advantages:

1. Industry leadership: As part of AIM Vaccine Group—the second-largest rabies vaccine manufacturer globally and the largest private full-industrial-chain vaccine group in China—we bring unmatched scale, expertise, and production capacity.

2. Full value chain control: We own four licensed manufacturing companies, three research institutes, and four R&D centers, ensuring comprehensive quality control from R&D through manufacturing to commercialization.

3. Global export experience: Products exported to South America, Central Asia, South Asia, Africa, West Asia, and Southeast Asia, with established government cooperation projects in Pakistan, Kenya, and Egypt.

4. R&D innovation: Five validated technology platforms, eight commercialized vaccines, and 20 products under development demonstrate our ongoing commitment to innovation and pipeline advancement.

5. Dedicated service: Professional marketing managers provide personalized support from initial inquiry to final delivery, with order locking and priority batch allocation for confirmed customers.

Our Service Commitment:

Upon receiving your inquiry, our corresponding marketing manager will contact you immediately. Once the factory receives your order requirements, we lock in the intended batch to secure your supply. After payment confirmation, we promptly arrange export shipment. Our experienced team handles all logistics coordination, documentation, and cold chain management to ensure a smooth and reliable procurement experience.

The Rabies Vaccine Vero Cell Against Rabies Virus Infection represents our mission to produce conscientious vaccines for the health of all. When you partner with AIM Honor, you gain more than a supplier—you gain a dedicated ally committed to advancing global public health through quality vaccines, reliable supply, and exceptional service. We invite you to contact us to discuss your procurement needs and explore how we can support your rabies control programs.

FAQ

Q: What are the storage requirements?

A: The vaccine must be stored and shipped between +2°C and +8°C, protected from light. Maintaining proper cold chain integrity is essential for preserving vaccine potency and ensuring product safety throughout its shelf life. Deviations from the recommended temperature range may compromise vaccine effectiveness.

Q: How long is the validity period?

A: The shelf life is 36 months from the date of manufacture when stored under the recommended temperature conditions. This extended validity period supports efficient inventory management and long-term procurement planning, reducing waste and operational costs for our partners.

Q: What is the minimum order quantity?

A: To ensure cost-effectiveness for both parties, please contact our sales representative for detailed MOQ information. Our team will work closely with you to determine the optimal order size based on your specific requirements, market demand, and budget considerations.

Q: Do you offer samples for evaluation?

A: Yes, we can provide a small number of vials for evaluation purposes. Please note that sample delivery is currently only available within China under ambient temperature conditions due to regulatory and logistical constraints. For international sample requests, please contact our sales team to discuss available options.

Q: What is the typical delivery time?

A: It usually takes approximately 30 working days after we receive your payment. The exact timeline may vary based on order quantity, destination country, specific shipping requirements, and current production schedules. Our team will keep you updated throughout the entire process.

Q: Are you a manufacturer or a trading company?

A: We are both a manufacturer and a trading company. As part of AIM Vaccine Group, we operate our own GMP-certified production facilities while also providing comprehensive export, distribution, and customer support services to international clients. This dual capability ensures both quality control and supply chain efficiency.

Q: Which regions do you currently export to?

A: Our products have been exported to multiple regions including Southeast Asia (20%), Africa (20%), West Asia (20%), South Asia (15%), Central Asia (15%), and South America (10%). We have established cooperation with relevant government authorities in Pakistan, Kenya, and Egypt, among other countries.

Q: What quality certifications do you hold?

A: We hold valid drug manufacturing licenses and operate under strict GMP standards. Our facilities undergo regular inspections to ensure compliance with national and international quality requirements. We are also actively advancing the PIC/S inspection process to further enhance our international recognition and market access.

Q: Do you participate in industry exhibitions?

A: Yes, we regularly participate in major international exhibitions to showcase our products and connect with global partners. Recent exhibitions include CPHI Europe, CPHI China, TIHE, VIF World 2025, and CPHI Middle East. These events allow us to demonstrate our manufacturing capabilities and discuss collaboration opportunities face-to-face.